On, or before, Monday, June 7, the FDA is expected to make a decision on aducanumab (Biogen), a new type of Alzheimer's treatment. If approved, the decision would be historic. Aducanumab would be the first drug to slow Alzheimer's disease, marking the beginning of a completely new future for Alzheimer's treatments.

The Alzheimer's Association urgently supports FDA approval of the treatment based on clinical trial results that showed a 22% reduction in cognitive and functional decline — something that could make a meaningful difference in the lives of individuals living with Alzheimer's and their families. With more than 6 million Americans living with Alzheimer's, the need for a treatment for a disease that has no survivors has never been greater.

Interviews are available ahead of, or immediately following, decision with the following:

• Alzheimer's Association leadership: to discuss impact of the FDA's decision on the Alzheimer's community and future research.
• Individuals living with early onset Alzheimer's and care partners: to discuss their personal experience with the therapy and hopes for the treatment.
• Science experts: to discuss the impact on research and the drug development pipeline.
• Neurologists, clinicians and health care experts: to discuss impact on care, treatment and the lives of people with early-onset Alzheimer's and their care partners.